Notre Dame researchers identify a TfR1 dimer that rises during ferroptosis, detectable in tissue and blood. Read the full study findings to learn more now.

Get the full details on Vyglxia now. FDA accepts Biohaven's resubmitted troriluzole NDA for spinocerebellar ataxia (SCA), ...

Menarini's Stemline licenses GIM-621, a first-in-class oral immuno-oncology agent from Georgiamune, in a deal worth up to $1.1B. Read the full story now.

Columbia researchers reveal how PARG inhibitors trap DNA-repair proteins to kill cancer cells, pointing to a possible ...

Stanford's AI digital twin predicts aspirin plus lansoprazole could delay labor about 15 times longer than aspirin alone.

Alcon acquires Neurotech for USD 550m, gaining ENCELTO, the only FDA-approved MacTel type 2 cell therapy. Read how it expands Alcon's retina portfolio.

Curis prices an $8.5M private placement at $0.51 per share to fund emavusertib CLL data in December 2026. Read the full story on the offering and runway.

Novartis's Cosentyx is now approved in Europe for polymyalgia rheumatica, the first IL-17A inhibitor for this use. Read the full story to learn more today.

Pennsylvania court awards Inovio $80.4M in breach-of-contract case over DNA plasmid supply deal with VGXI and GeneOne. Read the full ruling details now.

Roivant and Priovant report brepocitinib met the primary endpoint in Phase III uveitis trials. Read the latest results and ...

Kyverna reports one-year Phase II data for miv-cel in stiff person syndrome and plans a rolling BLA filing. Read the full ...

Muna Therapeutics' oral TREM2 modulator MNA-001 showed no serious adverse events in Phase I. Read how the Phase II ...